Results 101 to 110 of about 4,513 (159)

A New Adjuvant Treatment for Glioblastoma Using Aprepitant, Vortioxetine, Roflumilast and Olanzapine: The AVRO Regimen. [PDF]

Int J Mol Sci
Kast RE, Marques Vieira B, Barros da Silva E.   +2 more
europepmc   +1 more source

Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy

Tatsuhiko Sakamoto, Moeko Kado, Yoshitaka Saito, Kazuki Uchiyama, Ryota Kanno, Osamu TANIGUCHI, Yoh Takekuma, Jun Sakakibara‐Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara   +10 more
openalex   +2 more sources

GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma

, 2022
Yanying Li, Jingliang Wu, Lu Qiao, Xuemin Liu, Jiaxuan Wen, Xiaohui Qi, Jianhao Liu, Bo Lian, Bo Zhang, Hengyi Sun, Guixiang Tian   +10 more
openalex   +2 more sources

Evidence-Based Perioperative Prevention of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Laparoscopic Bariatric Surgery: A Scoping Review. [PDF]

J Clin Med
Mieszczański P, Jurczak M, Cylke R, Ziemiański P, Trzebicki J.   +4 more
europepmc   +1 more source

Evaluation of the Efficacy of Aprepitant on the Prevention of Chemotherapy-Induced Nausea and Vomiting and Quality of Life with Functional Living Index Emesis

, 2012
Görkem Aksu, İlhan Dolaşik, Fatih Ensaroğlu, Selçuk Yusuf Şener, Faden H. Aydin, Süleyman Temiz, D. Canoglu, Kazım Uygun   +7 more
openalex   +1 more source

Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Sarma I, Buragohain S, Lahon J, Banerjee P, Kumar S, Chetia R, Baishya P, Saikia D.   +7 more
europepmc   +1 more source

A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II) [PDF]

Kenichi Suzuki, Takashi Yokokawa, Takashi Kawaguchi, Shinya Takada, Shinya Tamaki, Yohei Kawasaki, Takumi Yamaguchi, Kei Koizumi, Takuma Matsumoto, Yukio Sakata, Yuichiro Arakawa, Hideaki Ayuhara, Mari Hosonaga, Masakazu Yamaguchi, Daiki Tsuji   +14 more
openalex   +1 more source

The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia

, 2020
Miguel Muñoz, Rafael Coveñas
openalex   +2 more sources

A Dual-Purpose Approach for an Anti-Emetic NK1R Antagonist as a Chemosensitizer and Cardioprotectant in a Preclinical Model of Triple-Negative Breast Cancer. [PDF]

Int J Mol Sci
Muñoz M, Coveñas R, Zuberi Y, Italia Z, Hoang T, Italia Z, Robinson P.   +6 more
europepmc   +1 more source

The Impact of Adding Aprepitant for the Patients Receiving Moderate Risk of Emetogenic Chemotherapy, a Prospective, Randomized, Cross-Over Trial.

, 2014
Ken Asaishi, Marco Durante, Miki Yoshida, Takayuki Kii, Shin Kuwakado, Hitoshi Nishitani, Fukutaro Shimamoto, Tetsuji Terazawa, Tatsuki Miyamoto, Kazuhide Higuchi   +9 more
openalex   +1 more source